Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23476158 | 0.83 | ADORA2A (0.33) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23641729 | 0.74 | CDK1 (0.31) | CDK1CDK2 | |
| SCHEMBL21137434 | 0.73 | ADORA2A (0.32) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24499630 | 0.73 | ADORA2A (0.35) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21011188 | 0.72 | DHFR (0.37) | CDK1CCNB1CDK2 | |
| SCHEMBL23641712 | 0.67 | ADORA2A (0.35) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL18782599 | 0.66 | ADORA2A (0.34) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24222091 | 0.62 | — | — | |
| SCHEMBL12049920 | 0.62 | ADA (0.31) | — | |
| SCHEMBL21347418 | 0.61 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-11578094-B2 | Charge-tagged nucleotides and methods of use thereof | ILLUMINA, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210138078-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA2A 70/4885ADORA1 34/4885ADORA2B 148/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ADORA2A 248/4885ADORA1 461/4885ADORA2B 163/4885 |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | ADORA2A 72/4885ADORA1 36/4885ADORA2B 150/4885 |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | ADORA2A 3614/4885ADORA1 4346/4885ADORA2B 2904/4885 |
| US-11578094-B2 | Charge-tagged nucleotides and methods of use thereof | POLN, POLRMT, POLM | ADORA2A 3662/4885ADORA1 3209/4885ADORA2B 3109/4885 |
| US-20210138078-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, RBM17 | ADORA2A 3614/4885ADORA1 4346/4885ADORA2B 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.